3.52
+0.12(+3.53%)
Currency In USD
| Previous Close | 3.4 |
| Open | 3.37 |
| Day High | 3.7 |
| Day Low | 3.17 |
| 52-Week High | 7.95 |
| 52-Week Low | 1.98 |
| Volume | 5.41M |
| Average Volume | 843,870 |
| Market Cap | 20.73M |
| PE | -3.03 |
| EPS | -1.16 |
| Moving Average 50 Days | 4.76 |
| Moving Average 200 Days | 3.77 |
| Change | 0.12 |
If you invested $1000 in Vivos Therapeutics, Inc. (VVOS) since IPO date, it would be worth $15.66 as of September 18, 2025 at a share price of $3.52. Whereas If you bought $1000 worth of Vivos Therapeutics, Inc. (VVOS) shares 3 years ago, it would be worth $128 as of September 18, 2025 at a share price of $3.52.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea Treatment
GlobeNewswire Inc.
Yesterday at 12:30 PM GMT
The European Journal of Pediatrics publishes the first-ever multicenter clinical trial results demonstrating that the Vivos DNA appliance — part of the company’s C.A.R.E. line of devices— is both safe and effective for children with OSALITTLETON, Col
Vivos Therapeutics Schedules Release of Second Quarter 2025 Financial Results and Conference Call
GlobeNewswire Inc.
Aug 19, 2025 12:30 PM GMT
Call Scheduled for today, Tuesday, August 19, 2025, at 5:00 pm ETLITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and technology company specializing i
Vivos Therapeutics Adds to Management Team to Support Expansion and Growth
GlobeNewswire Inc.
Jul 30, 2025 12:45 PM GMT
Two Key Hires Add Significant Experience and Strengthen Vivos’ Ability to Scale Its Promising New Sleep Testing Center and Direct Patient Treatment OperationsLITTLETON, Colo., July 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ: VVOS